Recent Release | 13 Jul 2020
Trade and transport margins in pharmaceuticals and other R&D-intensive industries
Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).
Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.
Tags:
You may be interested in
Post
Oxford Economics Launches Commercial Real Estate Megatrend Resilience Index
Our Commercial Real Estate Megatrend Resilience Index evaluates the resilience of CRE markets in relation to four critical megatrends.
Find Out More
Post
Oxford Economics Unveils Cutting-Edge AI Assistant Tool
Oxford Economics is thrilled to announce the beta launch of its AI Assistant, an advanced artificial intelligence tool designed to enhance client experiences by streamlining access to and analysis of global macroeconomic data.
Find Out More
Post
Oxford Economics ranks top in the FocusEconomics Analyst Forecast Awards 2024
Oxford Economics has once again been recognized as one of the top performers in the 2024 FocusEconomics Analyst Forecast Awards.
Find Out More